JP2016500001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500001A5 JP2016500001A5 JP2015531678A JP2015531678A JP2016500001A5 JP 2016500001 A5 JP2016500001 A5 JP 2016500001A5 JP 2015531678 A JP2015531678 A JP 2015531678A JP 2015531678 A JP2015531678 A JP 2015531678A JP 2016500001 A5 JP2016500001 A5 JP 2016500001A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- protein
- residues
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000018102 proteins Nutrition 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 22
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 150000001413 amino acids Chemical group 0.000 claims 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- 229940024606 amino acid Drugs 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 229960001230 asparagine Drugs 0.000 claims 6
- 235000009582 asparagine Nutrition 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 5
- 229960000310 isoleucine Drugs 0.000 claims 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 5
- 229930182817 methionine Natural products 0.000 claims 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 206010068304 Congenital nephrogenic diabetes insipidus Diseases 0.000 claims 1
- 206010021036 Hyponatraemia Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 230000002686 anti-diuretic effect Effects 0.000 claims 1
- 229940124538 antidiuretic agent Drugs 0.000 claims 1
- 239000003160 antidiuretic agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306120.2 | 2012-09-17 | ||
| EP12306120.2A EP2708235A1 (en) | 2012-09-17 | 2012-09-17 | Peptide antagonists of the vasopressin-2 receptor |
| PCT/IB2013/058615 WO2014041526A1 (en) | 2012-09-17 | 2013-09-17 | Peptide antagonists of the vasopressin-2 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016500001A JP2016500001A (ja) | 2016-01-07 |
| JP2016500001A5 true JP2016500001A5 (cg-RX-API-DMAC7.html) | 2016-11-04 |
| JP6392758B2 JP6392758B2 (ja) | 2018-09-19 |
Family
ID=46963639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531678A Active JP6392758B2 (ja) | 2012-09-17 | 2013-09-17 | バソプレッシン−２レセプターのペプチドアンタゴニスト |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9631001B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2708235A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6392758B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102135954B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104684574B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013316700B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015005750B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2884361C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2895189T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2664747T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX362664B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ706202A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015114320A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014041526A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021528476A (ja) * | 2018-06-28 | 2021-10-21 | サルアクア ダイアグノスティックス， インコーポレイテッド | ハプトグロビン関連タンパク質と関係する組成物および方法 |
| EP3929209A1 (en) * | 2020-06-24 | 2021-12-29 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Vasopressin-2 receptor antagonist peptides and uses thereof |
| CN115820734B (zh) * | 2022-11-11 | 2024-12-13 | 北京希诺谷生物科技有限公司 | 中枢性尿崩症疾病模型犬的建立方法 |
| CN116425888B (zh) * | 2023-04-24 | 2024-11-05 | 徐州医科大学 | 一种多肽tat-v2r1c及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| WO2007019267A1 (en) | 2005-08-03 | 2007-02-15 | Mineuet Therapeutics Ltd. | MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR α (TNF-α) AND TREATING HUMAN DISEASES OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-α |
| US8343760B2 (en) | 2008-06-05 | 2013-01-01 | University Of Maryland, Baltimore | p53 activator peptides |
-
2012
- 2012-09-17 EP EP12306120.2A patent/EP2708235A1/en not_active Withdrawn
-
2013
- 2013-09-17 NZ NZ706202A patent/NZ706202A/en unknown
- 2013-09-17 MX MX2015003225A patent/MX362664B/es active IP Right Grant
- 2013-09-17 CN CN201380048382.9A patent/CN104684574B/zh active Active
- 2013-09-17 US US14/427,733 patent/US9631001B2/en active Active
- 2013-09-17 DK DK13801742.1T patent/DK2895189T3/en active
- 2013-09-17 CA CA2884361A patent/CA2884361C/en active Active
- 2013-09-17 AU AU2013316700A patent/AU2013316700B2/en active Active
- 2013-09-17 RU RU2015114320A patent/RU2015114320A/ru not_active Application Discontinuation
- 2013-09-17 KR KR1020157009903A patent/KR102135954B1/ko active Active
- 2013-09-17 ES ES13801742.1T patent/ES2664747T3/es active Active
- 2013-09-17 WO PCT/IB2013/058615 patent/WO2014041526A1/en not_active Ceased
- 2013-09-17 BR BR112015005750-0A patent/BR112015005750B1/pt active IP Right Grant
- 2013-09-17 JP JP2015531678A patent/JP6392758B2/ja active Active
- 2013-09-17 EP EP13801742.1A patent/EP2895189B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011502479A5 (cg-RX-API-DMAC7.html) | ||
| FI3256579T3 (fi) | Kysteiiniproteaasi | |
| CA2880649C (en) | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) | |
| US20230212240A1 (en) | Wnt signaling agonist molecules | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| US10647742B2 (en) | Method for synthesizing etelcalcetide | |
| TW201630620A (zh) | Ｈｌａ-ａ＊１１０１限制性ｗｔ１胜肽之用途 | |
| JP2018506286A5 (cg-RX-API-DMAC7.html) | ||
| JP2014525901A5 (cg-RX-API-DMAC7.html) | ||
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| TW201702266A (zh) | 抗ｐａｃａｐ抗體及其用途 | |
| JP2015134758A5 (cg-RX-API-DMAC7.html) | ||
| JP2016500001A5 (cg-RX-API-DMAC7.html) | ||
| RU2014132108A (ru) | Slit-robo сигналинг для диагностики и лечения заболевания почек | |
| JP7079779B2 (ja) | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 | |
| JP2012530060A5 (cg-RX-API-DMAC7.html) | ||
| JP2015508771A5 (cg-RX-API-DMAC7.html) | ||
| JP2014506452A5 (cg-RX-API-DMAC7.html) | ||
| EP4157867A1 (en) | Human recombinant monoclonal antibody against sars-cov-2 spike glycoprotein | |
| JP2011521661A5 (cg-RX-API-DMAC7.html) | ||
| JP2014533098A5 (cg-RX-API-DMAC7.html) | ||
| RU2015114320A (ru) | Пептидные антагонисты рецептора 2 вазопрессина | |
| JP2017519763A5 (cg-RX-API-DMAC7.html) | ||
| CN119013034A (zh) | 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 | |
| TW202122410A (zh) | 鈣敏感受體激動劑化合物及其應用 |